High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery.
Today, the toolbox for high-throughput screening features traditional label-dependent approaches and novel label-free technologies. Researchers determine which methodology offers the most promising path forward for their target, taking into account assay sensitivity, data quality, costs, and speed. Moreover, many companies opt to outsource drug discovery efforts to contract research organizations, which offer a particular expertise and an established discovery infrastructure to lead hit identification and hit-to-lead programs.
In this white paper, we discuss important aspects to consider when choosing a methodology for drug discovery.